Evommune, Inc. (EVMN) Stock Statistics & Valuation Metrics

Evommune, Inc. has a market cap or net worth of $848.59M. The enterprise value is $268.84M.

Evommune, Inc. has 36,018,370 shares outstanding. The number of shares has decreased by -2.65% in one year.

Evommune, Inc.’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -39.05%.

The current PE Ratio of Evommune, Inc. is ―. Evommune, Inc.’s PEG ratio is 1.98.

In the last 12 months, Evommune, Inc. had revenue of 13.00M and earned -68.87M in profits. Earnings per share was -2.18.

In the last 12 months, operating cash flow was -76.44M and capital expenditures -235.00K, giving a free cash flow of -76.68M billion.

Evommune, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Evommune, Inc. upcoming earnings date is Mar 5, 2026, After Close (Confirmed).

Evommune, Inc. as a current ratio of 8.57, with Debt / Equity ratio of 1.00%

In the past 12 months, Evommune, Inc. has paid 0.00 in taxes.

Evommune, Inc. EV to EBITDA ratio is -6.25, with an EV/FCF ratio of -6.49.

Evommune, Inc. has $149.20M in cash and marketable securities with $2.06M in debt, giving a net cash position of $147.14M billion.

Gross margin is 89.32%, with operating margin of -623.62%, and net profit margin of -529.77%.

The average price target for Evommune, Inc. is $49.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy